Invivyd (NASDAQ:IVVD) Earns Buy Rating from D. Boral Capital

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating reaffirmed by equities researchers at D. Boral Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $9.00 price target on the stock.

IVVD has been the subject of several other reports. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Invivyd in a research report on Monday, February 24th. Morgan Stanley reduced their price objective on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research report on Wednesday, November 20th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $7.89.

Invivyd Trading Down 2.8 %

NASDAQ:IVVD opened at $1.03 on Wednesday. The stock has a 50 day moving average of $0.91 and a 200-day moving average of $0.87. The firm has a market capitalization of $123.20 million, a PE ratio of -0.53 and a beta of 0.61. Invivyd has a 52 week low of $0.35 and a 52 week high of $4.74.

Insiders Place Their Bets

In other Invivyd news, Director Terrance Mcguire sold 86,545 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $0.48, for a total value of $41,541.60. Following the completion of the sale, the director now directly owns 3,170,231 shares in the company, valued at $1,521,710.88. This represents a 2.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 816,466 shares of company stock worth $423,214 over the last ninety days. Company insiders own 17.90% of the company’s stock.

Institutional Investors Weigh In On Invivyd

Institutional investors have recently added to or reduced their stakes in the company. Proficio Capital Partners LLC acquired a new stake in Invivyd in the third quarter worth approximately $27,000. Jane Street Group LLC lifted its position in shares of Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock valued at $52,000 after acquiring an additional 87,358 shares during the last quarter. Barclays PLC lifted its position in shares of Invivyd by 7.8% during the 4th quarter. Barclays PLC now owns 127,180 shares of the company’s stock valued at $56,000 after acquiring an additional 9,207 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Invivyd during the 4th quarter valued at $74,000. Finally, JPMorgan Chase & Co. lifted its position in shares of Invivyd by 644.1% during the 4th quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company’s stock valued at $114,000 after acquiring an additional 222,375 shares during the last quarter. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.